- $1.95bn
- $1.66bn
- $526.50m
- 32
- 25
- 93
- 48
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.29 | ||
| Price to Tang. Book | 3.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.7 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -11.03% | ||
| Return on Equity | -31.05% | ||
| Operating Margin | -38.73% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 94.4 | 128.4 | 256.7 | 429.8 | 526.5 | 658.61 | 874.58 | 50.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lemonade, Inc. offers renters, homeowners, car, pet, and life insurance. The Company operates through the United States, Europe, including the United Kingdom, providing insurance products to customers through various sales channels. The Company's digital substrate enables it to integrate marketing and onboarding with underwriting and claims processing, collecting, and deploying data. Its technology includes Data Advantage, AI Maya, AI Jim, CX.AI, Forensic Graph, Blender, and Cooper. AI Maya, its onboarding and customer experience bot, uses natural language to guide customers in joining the Company. AI Jim, its claims bot, takes the first notice of loss from its customer without human intervention. It offers pet insurance that covers diagnostics, procedures, medication, accidents or illness. Even its basic pet insurance offering covers blood tests, urinalysis, lab work, and computed tomography scans.
Directors
- Daniel Schreiber CHM (50)
- Shai Wininger PRE (47)
- Timothy Bixby CFO (56)
- Adina Eckstein COO (36)
- Sean Burgess OTH
- Jorge Espinel OTH (49)
- John Peters OTH (49)
- Joel Cutler IND (63)
- Michael Eisenberg IND (49)
- Silvija Martincevic IND (41)
- Irina Novoselsky IND (36)
- Mwashuma Nyatta IND (41)
- Caryn Seidman- Becker IND (48)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 17th, 2015
- Public Since
- July 2nd, 2020
- No. of Shareholders
- 149
- No. of Employees
- 1,235
- Sector
- Insurance
- Industry
- Financials
- Exchange
New York Stock Exchange- Shares in Issue
- 72,820,080
- Address
- 5 CROSBY STREET, 3RD FLOOR, NEW YORK, 10013
- Web
- https://www.lemonade.com/
- Phone
- +1 null8447338666
- Auditors
- Ernst & Young LLP
Upcoming Events for LMND
Lemonade Inc Annual Shareholders Meeting
Q2 2025 Lemonade Inc Earnings Release
Similar to LMND
Aegon
New York Stock Exchange
Aflac
New York Stock Exchange
Allstate
New York Stock Exchange
Ambac Financial
New York Stock Exchange
American Financial
New York Stock Exchange
FAQ
What is the LEMONADE share price?
As of Today at 21:43 UTC, shares in LEMONADE are trading at $26.78. This share price information is delayed by 15 minutes.
How has the LEMONADE share price performed this year?
Shares in LEMONADE last closed at $26.78 and the price had moved by +70.14% over the past 365 days. In terms of relative price strength the LEMONADE share price has outperformed the S&P500 Index by +59.98% over the past year.
What are the analyst and broker recommendations for LEMONADE?
The overall consensus recommendation for LEMONADE is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the LEMONADE dividend yield?
LEMONADE does not currently pay a dividend.
Does LEMONADE pay a dividend?
LEMONADE does not currently pay a dividend.
When does LEMONADE next pay dividends?
LEMONADE does not currently pay a dividend.
How do I buy LEMONADE shares?
To buy shares in LEMONADE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of LEMONADE?
As of the previous close price of $26.78, shares in LEMONADE had a market capitalisation of $1.95bn.
Where are LEMONADE shares listed?
Here are the trading details for LEMONADE:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: LMND
What kind of share is LEMONADE?
Based on an overall assessment of its quality, value and momentum LEMONADE is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a LEMONADE share price forecast for 2025?
The analyst consensus target price for shares in LEMONADE is $30.57. That is 14.15% above the last closing price of $26.78.
Analysts covering LEMONADE currently have a consensus Earnings Per Share (EPS) forecast of -$2.81 for the next financial year.
Find out moreWhat is the trend in the LEMONADE share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like LEMONADE. Over the past six months, its share price has outperformed the S&P500 Index by +59.63%.
As of the last closing price of $26.78, shares in LEMONADE were trading -4.88% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the LEMONADE PE Ratio?
The LEMONADE PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $26.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of LEMONADE?
LEMONADE's management team is headed by:
- Daniel Schreiber - CHM
- Shai Wininger - PRE
- Timothy Bixby - CFO
- Adina Eckstein - COO
- Sean Burgess - OTH
- Jorge Espinel - OTH
- John Peters - OTH
- Joel Cutler - IND
- Michael Eisenberg - IND
- Silvija Martincevic - IND
- Irina Novoselsky - IND
- Mwashuma Nyatta - IND
- Caryn Seidman- Becker - IND